NuVasive (NUVA) has strung together four quarters of above-market growth, but investors remain skeptical as to just how quickly new management can get this business back on a better path. Progress on operating margin expansion has been frustratingly inconsistent, though management has made it clear that 2019 is a re-investment year, and it will take time for the company to recover from the mistakes of the former management team, including supporting/ignoring the wrong product development opportunities.
The shares look undervalued to me on both cash flow and revenue growth, and I believe the